Core Viewpoint - Yuan Da Pharmaceutical (00512) has demonstrated robust growth in its mid-year performance, achieving a record revenue of approximately HKD 6.11 billion, with significant contributions from innovative and barrier products [1] Financial Performance - The company reported a revenue of approximately HKD 6.11 billion for the first half of the year, marking a historical high [1] - Revenue from innovative and barrier products accounted for about 51% of total revenue, an increase of nearly 15 percentage points year-on-year [1] - Excluding the impact of centralized procurement and exchange rates, the company's revenue grew approximately 13% year-on-year [1] - The net profit for the period was approximately HKD 1.17 billion [1] Product Development - On July 7, the Yttrium-90 microsphere injection received early formal approval from the US FDA for a new indication for unresectable hepatocellular carcinoma (HCC), with no restrictions on tumor diameter [1] - The product, Yigan Tai, is the first and only selective internal radiation therapy product approved by the FDA for both unresectable HCC and colorectal cancer liver metastases [1] - Since its approval in China, the Yttrium-90 microsphere injection has rapidly gained traction, treating nearly 2,000 patients by the end of 2024 [1] - The product is expected to achieve nearly HKD 500 million in sales revenue in 2024, with a year-on-year growth rate exceeding 140% [1]
港股异动 | 远大医药(00512)绩后涨超4% 上半年收入创历史新高 易甘泰有望引领公司业绩高增